ViroGates is an international Medtech company headquartered North of Copenhagen, in the heart of Medicon Valley.

Group photo of the people working at ViroGates January 2020

About ViroGates

ViroGates was founded in 2001 based on an invention from Hvidovre University Hospital, Denmark.

Inventor and co-founder Jesper Eugen-Olsen initially discovered the utility of the biomarker suPAR in HIV. More than 700 publications have followed, substantiating suPAR as one of the most promising prognostic biomarkers across diseases. ViroGates has developed a patented product line called suPARnostic® to make the suPAR test commercially available.

The suPAR biomarker predicts negative patient outcomes across diseases by measuring the activation level of the immune system. suPARnostic® is a fast and reliable prognostic biomarker that enables healthcare professionals to make quick and informed patient triaging decisions at emergency departments.

Implementing suPARnostic® in clinical care saves critical resources and valuable time, and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes.

suPARnostic® delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay.

Seamlessly implemented by clinicians and laboratory technicians, suPARnostic® products fit existing workflows in hospitals, are approved for all the major clinical chemistry analyzers, and delivers results in less than 20 minutes.

How suPARnostic® works at the Emergency department

Step 1

A patient is admitted to the emergency department for observation

Step 2

The patient’s blood sample is drawn

Step 3

The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.

Step 4

The physician gets the result and makes a triage decision

“The key challenge for the Emergency Department is to identify ill patients faster, make diagnoses faster, find the right specialist faster and initiate the right treatment faster.”

– MD, Chief Physician Inger Søndergaard, Herlev Hospital, Copenhagen

Our Vision and Mission

We envision a healthcare system where the suPAR biomarker makes a difference by providing information that empowers clinicians to save lives and provide patients with the treatment they need.

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates